Jacobio Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
207
- Stock Symbol
-
01167
- Investments
-
1
- Share Price
-
$0.51
- (As of Friday Closing)
Jacobio Pharmaceuticals General Information
Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
Contact Information
Website
www.jacobiopharma.comCorporate Office
- Building 8
- Number 105 Jinghai 3rd Road, BDA
- Beijing, 101111
- China
Corporate Office
- Building 8
- Number 105 Jinghai 3rd Road, BDA
- Beijing, 101111
- China
Jacobio Pharmaceuticals Stock Performance
As of 20-Nov-2026, Jacobio Pharmaceuticals’s stock price is $0.51. Its current market cap is $401M with 782M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.51 | $0.53 | $0.50 - $1.19 | $401M | 782M | 1.78M | $0.10 |
Jacobio Pharmaceuticals Financials Summary
As of 30-Jun-2026, Jacobio Pharmaceuticals has a trailing 12-month revenue of $106M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 344,269 | 513,357 | 10,399 | 215,387 |
| Revenue | 105,573 | 7,443 | 21,700 | 8,978 |
| EBITDA | 73,402 | (19,738) | (22,537) | (52,693) |
| Net Income | 73,404 | (20,300) | (21,700) | (50,760) |
| Total Assets | 274,249 | 186,420 | 186,185 | 206,032 |
| Total Debt | 23,521 | 23,606 | 20,832 | 29,613 |
Jacobio Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jacobio Pharmaceuticals Comparisons
Industry
Financing
Details
Jacobio Pharmaceuticals Competitors (43)
One of Jacobio Pharmaceuticals’s 43 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Tvardi Therapeutics | Formerly VC-backed | Sugar Land, TX | ||||
| Immutep | Corporation | Sydney, Australia | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Jacobio Pharmaceuticals Signals
Jacobio Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Jacobio Pharmaceuticals Investments (1)
Jacobio Pharmaceuticals’s most recent deal was a Later Stage VC with HebeCell for . The deal was made on 31-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HebeCell | 31-Aug-2021 | Later Stage VC | Other Healthcare Technology Systems |
Jacobio Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
28.21 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Jacobio Pharmaceuticals FAQs
-
When was Jacobio Pharmaceuticals founded?
Jacobio Pharmaceuticals was founded in 2015.
-
Where is Jacobio Pharmaceuticals headquartered?
Jacobio Pharmaceuticals is headquartered in Beijing, China.
-
What is the size of Jacobio Pharmaceuticals?
Jacobio Pharmaceuticals has 207 total employees.
-
What industry is Jacobio Pharmaceuticals in?
Jacobio Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Jacobio Pharmaceuticals a private or public company?
Jacobio Pharmaceuticals is a Public company.
-
What is Jacobio Pharmaceuticals’s stock symbol?
The ticker symbol for Jacobio Pharmaceuticals is 01167.
-
What is the current stock price of Jacobio Pharmaceuticals?
As of 20-Nov-2026 the stock price of Jacobio Pharmaceuticals is $0.51.
-
What is the current market cap of Jacobio Pharmaceuticals?
The current market capitalization of Jacobio Pharmaceuticals is $401M.
-
What is Jacobio Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Jacobio Pharmaceuticals is $106M.
-
Who are Jacobio Pharmaceuticals’s competitors?
Dicerna Pharmaceuticals, Tvardi Therapeutics, Immutep, Amunix Pharmaceuticals, and Alnylam Pharmaceuticals are some of the 43 competitors of Jacobio Pharmaceuticals.
-
What is Jacobio Pharmaceuticals’s annual earnings per share (EPS)?
Jacobio Pharmaceuticals’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process